<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04143841</url>
  </required_header>
  <id_info>
    <org_study_id>CLP-10003</org_study_id>
    <nct_id>NCT04143841</nct_id>
  </id_info>
  <brief_title>Viveye Ocular Magnetic Neurostimulation System (OMNS) for the Management of Severe Dry Eye Disease</brief_title>
  <acronym>OMNS</acronym>
  <official_title>A Pilot Study to Evaluate the Safety and Effectiveness of the Viveye Ocular Magnetic Neurostimulation System (OMNS) for the Management of Severe Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epitech Mag Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Epitech Mag Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and effectiveness of Viveye OMNS&#xD;
      non-invasive treatment for management of the signs and symptoms of severe dry eye disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Financial constraints&#xD;
  </why_stopped>
  <start_date type="Actual">October 30, 2019</start_date>
  <completion_date type="Actual">January 6, 2021</completion_date>
  <primary_completion_date type="Actual">January 6, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best corrected visual acuity (BCVA)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Frequency of treatment related deterioration in BCVA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraocular Pressure (IOP)</measure>
    <time_frame>12 weeks</time_frame>
    <description>IOP results will be summarized descriptively. 95% confidence intervals for the difference between treatment arms at each visit will be presented, assuming t-distribution.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Slit lamp biomicroscopy</measure>
    <time_frame>12 weeks</time_frame>
    <description>The percent related to worsening in ocular pathological changes observed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of device/treatment related adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Rate of device/treatment related Incidence of Adverse events (AE) will be presented in tabular form by seriousness, severity and relation to treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fluorescein corneal staining</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline in fluorescein corneal staining score (NEI Scale 0-15) per treatment arm and visit (lower scores mean a better outcome.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular discomfort questionnaires</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline in ocular discomfort questionnaires (Standard Patient Evaluation of Eye Dryness - SPEED) per treatment arm and visit. score from 0 to 28, higher scores mean a worse outcome. (Reduction in SUM score = improvement)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <condition>ATD</condition>
  <condition>Sjogren's Syndrome</condition>
  <arm_group>
    <arm_group_label>Single treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single treatment will be administered for both eyes for each subject. The treatment will be administered for 11 minutes per treated eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single sham treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>A single treatment will be administered for both eyes for each subject. The treatment will be administered for 11 minutes per treated eye.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Viveye OMNS treatment</intervention_name>
    <description>The Viveye OMNS treatment ( ~30 min) will be applied once, during the treatment visit only</description>
    <arm_group_label>Single treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Viveye OMNS sham treatment</intervention_name>
    <description>The Viveye OMNS sham treatment ( ~30 min) will be applied once, during the treatment visit only</description>
    <arm_group_label>Single sham treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females, 18-80 years old&#xD;
&#xD;
          2. Subjects with severe aqueous deficient dry eye disease (concomitant meibomian gland&#xD;
             disease is permitted):&#xD;
&#xD;
               1. SPEED questionnaire score ≥ 10 AND&#xD;
&#xD;
               2. Fluorescein Corneal Staining Score (FCSS) ≥ 5 NEI score in at least in one eye&#xD;
                  AND&#xD;
&#xD;
               3. Schirmer score ≤ 10 mm in at least one eye (at screening or treatment day&#xD;
                  pre-treatment)&#xD;
&#xD;
          3. No contact lens wear for at least seven days prior to the Screening Visit and&#xD;
             willingness to forego contact lens wear for the duration of the study;&#xD;
&#xD;
          4. Literacy, able to speak English or Hebrew, and able to complete questionnaires&#xD;
             independently;&#xD;
&#xD;
          5. Willing and able to sign the informed consent form and deemed capable of complying&#xD;
             with the requirements of the study protocol (tests and follow-up visits).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Significant anterior blepharitis including signs of Demodex eyelid infection;&#xD;
&#xD;
          2. If the subject is using prescription dry eye ophthalmic drug such as Restasis&#xD;
             (Cyclosporine A 0.05% ophthalmic emulsion), Xiidra (Lifitegrast), Cequa (Cyclosporine&#xD;
             0.09% ophthalmic solution), and the medication has not been used regularly for the&#xD;
             past 3 months prior to screening visit;&#xD;
&#xD;
          3. Change in eye lubricant type usage in the last 1 month prior enrollment. Use of any&#xD;
             device to manage DED within 1 month of Screening Visit;&#xD;
&#xD;
          4. Punctal plugs are present at screening that were inserted in the last 30 days prior&#xD;
             enrollment, or intracanalicular plug that were inserted in the last 6 months in any&#xD;
             eyelid;&#xD;
&#xD;
          5. Corneal transplant in either or both eyes;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>E.Wolfson MC</name>
      <address>
        <city>Holon</city>
        <zip>5822012</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SZMC</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 24, 2019</study_first_submitted>
  <study_first_submitted_qc>October 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

